Protocol Ledger

NCT07827599 · Phase III · RECRUITING

A Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in Chinese Participants

Interventional Phase III clinical trial protocol NCT07827599 sponsored by Roche / Genentech in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-10-16 Enrollment: 325 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07827599
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)325 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07827599
Protocol FieldVerified Registry Value
NCT IdentifierNCT07827599
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment325 participants (ESTIMATED)
Registered Start Date2026-10-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07827599
Hospital Research SiteLocationSite Profile
Huashan Hospital Affiliated to Fudan UniversityShanghai, ChinaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI